Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging

The 99m Tc-MIBI radiopharmaceutical has been used in nuclear medicine in Indonesia for myocardial imaging . BATAN researchers have mastered the technology to manufacture MIBI as a liophylized kit. A reformulation of MIBI radiopharmaceutical has been conducted to improve the stability of the kit especially in the liquid-phase kit. Basically, radiopharmaceuticals in liquid form are not different from the dry kit. However in the  manufactur ing of liquid - phase kit, l yophilization process was not done. To improve the stability of liquid kit, a r eformulat ion of the components was conducted by using two separate vials (Formulation 2) and the characteristics were compared with the one-vial formulation (Formulation 1) .  The MIBI Formulation 2 consists of two vials , v ial A containing 0.06 mg of SnCl 2 2H 2 O and 2.6 mg Sodium Citrate 2H 2 O and vial B containing 0.5 mg of [Cu(MIBI) 4 ]BF 4 , 1 mg of cysteine hydrochloride , and 20 mg of mannitol. The purpose s of this study were to determine the stability of two different formulations of MIBI as a liquid -phase kit, to compare their  stability in different storage condition such as in refrigerator and freezer, and to compare the ratio of activities attained between target and nontarget  organs after injection to animal model . As a diagnostic agent, MIBI was reconstituted with Technetium-99m as radionuclide tracer to 99m Tc-MIBI labeled compound. The radiochemical purity of 99m Tc-MIBI was determined by chromatography method using alumina thin-layer chromatography paper as the stationary phase and ethanol 95% as the mobile phase. The results showed MIBI F ormulation 2 has a higher stability than F ormulation 1 . Formulation 2 also maintained  a 96 . 68%  radio chemical purity under 52-day storage and attained  a  target-to- nontarget activity ratio of 8.22 . Received:  04 October 2014 ; Revised:  10 November 2015 ; Accepted:  25 November 2015